



1646

PTO/SB/92 (08-00)

Approved for use through 10/31/2002: OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on March 14, 2001
Date

GINOLA L. JOHNSON
Signature

GINOLA L. JOHNSON
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

09/728,653

PH-7118

Information Disclosure Statement

Information Disclosure Statement by Application

18 References

RECEIVED
MAR 21 2001
TECH CENTER 1600/2900

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#2/enc
18/38/01

RECEIVED

MAR 21 2001

TECH CENTER 1600/2900

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF: CASE NO.: PH-7118

HAN

SERIAL NO.: 09/728,653 GROUP ART UNIT: 1646

FILED: December 1, 2000 EXAMINER: To be assigned

FOR: Alpha-Ketoamide Inhibitors
Of Hepatitis C Virus NS3
Protease

Wilmington, Delaware
DATE: March 14, 2001

Box DD
Commissioner of Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore:
- () Certification in Accordance with \$1.97(e) is set forth below.
- () The fee of \$240.00 as set forth in \$1.17(p) is attached.
- () In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).

Please charge any deficiency or credit any overpayment to Deposit Account No. 04-1928.

There are no listed references which are not in the English language or do not contain an English language abstract.

Respectfully submitted,

Louis A. Piccone

Louis A. Piccone
Attorney for Applicants
Registration No. 41,452
Telephone: (302) 992-2231